Thermo Fisher Scientific has entered into a definitive agreement to purchase One Lambda, a provider of transplant diagnostics services, for $925m in cash.
One Lambda offers human leukocyte antigen (HLA) typing and antibody detection assays, which are used by transplant centres for tissue typing to detect the presence of antibodies that can lead to transplant rejection, as well as to determine the compatibility of donors and recipients pre-transplant.
The transaction, which is subject to post-closing adjustment, is expected to be completed in the fourth quarter of 2012.
The transaction also expects to be immediately accretive upon close and add between $0.09 to $0.11 to Thermo Fisher’s 2013 adjusted earnings per share (EPS).
Marc N. Casper, Thermo Fisher president and chief executive officer, said One Lambda tests are widely used across transplant-testing centres to improve workflow and patient outcomes.
"With its strong technology platform, high margin profile and good growth prospects, the business is perfectly aligned with our specialty in vitro diagnostics strategy," Casper added.
"From a financial perspective, we expect One Lambda to be immediately accretive to our adjusted EPS and to yield a strong return on invested capital."
George M. Ayoub, One Lambda co-founder president and chief executive officer, said: "I believe that, together, we will increase the use of human leukocyte antigen (HLA) typing and antibody detection to accelerate growth and improve the success rate of transplantation."
Image: Thermo Fisher Scientific headquarters in Waltham, Massachusetts, US. Photo courtesy of: Coolcaesar.